To NASDAQ OMX Copenhagen A/S Announcement No. 35-08 / Copenhagen, 22 December 2008 Copenhagen, Denmark, 22 December 2008 - TopoTarget A/S (OMX: TOPO) announces an update on phase II data with APO866 in three clinical studies. APO866 has demonstrated a confirmed partial response (PR) in Cutaneous T-Cell Lymphoma (CTCL) and transient reductions in white blood cells in patients with B-cell Chronic Lymphocytic Leukaemia (B-CLL) whereas there was no clinical effect in melanoma. APO866 -a specific inhibitor of the key enzyme involved in the synthesis of NAD+ is administered by continuous infusion at 0.126 mg/m2/hr for 96 hours in a 28 day schedule and is reasonably well tolerated. While this ongoing CTCL study has shown encouraging signs of clinical activity, five more patients are required for the interim analysis. “APO0866 rights came to TopoTarget through the acquisition of Apoxis in 2007 and we have evaluated the drug in three phase II studies. I am happy to announce that we now have evidence activity in cancer patients. APO866 has demonstrated a confirmed PR in cutaneous T-Cell lymphoma and transient reductions in white blood cells in patients with B-CLL”, said Peter Buhl Jensen, Professor, MD, CEO of TopoTarget. “From our laboratory investigations we believed that the NAD+ target could be very important in cancer treatment and this confirms our beliefs. It is very difficult to find anticancer drugs with new mechanisms of action and activity beyond models. We still have a long way to go but now we know that this target and mechanism works also in cancer patients”, Peter Buhl Jensen further commented. Today's announcement does not change TopoTarget's full-year financial guidance for 2008. TopoTarget A/S For further information, please contact: Peter Buhl Jensen Telephone +45 39 17 94 99 CEO Mobile +45 21 60 89 22
APO866 an NAD+ inhibitor shows clinical activity in CTCL + B-CLL. APO866 is selected via TopoTarget's discovery technology
| Source: Topotarget